PRESS RELEASE
For Immediate Release:

PHARMA HOLDINGS to market new specialty pharmacy medications …

JUPITER, FL - (May 2, 2007) – Pharma Holdings, Inc.’s has agreed to become the marketing and distribution agent for a new line of specialty pharmacy medications that have recently become approved by the FDA here in the USA. 

These products include Perlane, Juvederm, Radiesse, and a new generic form of Botulism Toxin Type A (more commonly known as Botox). Many of these items have been available throughout the world, but have only recently received the FDA approval for sale in the United States. Prospects for these medications include plastic surgeons, dermatologists and pain clinics. Pharma plans to institute an aggressive marketing and advertising campaign to launch the product. This campaign will include direct mail, space ads, television and trade shows.

Pharma Holdings plans to formally introduce these products as part of an overall advertising campaign that will include telemarketing, direct mail and trade advertising. According to Edward Klapp, CEO, Director and Secretary of Pharma Holdings, Inc., these products are expected to generate sales of nearly $50 million in the next year, and have the potential to reach nearly $1 billion per year over the next ten years.

Pharma Holdings already distributes products on a global basis, including diabetic care, DME products, maintenance medications, and other medical devices. Pharma has been in the healthcare distribution business for fours years and has grown into a multi-national corporation with sales reaching into more than 20 countries.   

For additional information about Pharma Holdings contact, Edward Klapp, or visit (www.pharmaholding.com)